Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Epcoritamab + R2 demonstrated sustained efficacy with manageable safety, regardless of baseline risk factors, including those traditionally associated with higher- or lower-risk disease factors.

  60% confidence

• Epcoritamab + R2 delivered consistent and sustained efficacy benefits across clinically relevant subgroups including FLIPI score, POD24 status, and patient fitness in R/R follicular lymphoma patients.

  60% confidence

• Progression-free survival benefits favored epcoritamab + R2 with hazard ratios consistently below 0.3 across all evaluated subgroups, indicating a substantially reduced risk of disease progression or death.

  60% confidence

• The EPCORE FL-1 trial, bolstered by this subgroup analysis, established fixed-duration epcoritamab in combination with R2 for relapsed or refractory follicular lymphoma. It delivers consistent efficacy and a manageable safety profile, regardless of comorbidity burden.

  60% confidence

Cited in these Via News reports

• Six FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst Calendar →